Benznidazole is the front-line drug used to treat infections with Trypanosoma cruzi, the
causative agent of Chagas disease. However, for reasons that are unknown, treatment …

A major contributor to treatment failure in Chagas disease, caused by infection with the
protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the …

The insect-transmitted protozoan parasite Trypanosoma cruzi is the causative agent of
Chagas disease, and infects 5–8 million people in Latin America. Chagas disease is …

Chronic Trypanosoma cruzi infections are typically lifelong, with small numbers of parasites
surviving in restricted tissue sites, which include the gastrointestinal tract. There is …

Chagas disease agent, Trypanosoma cruzi, is capable to persist after prolonged drug
treatment using effective drugs. The reason of treatment failure is not known, but recent …

The article by Francisco et al.(1) describes the use of a biolumi-nescence imaging system
(2) to evaluate the efficacy of benznidazole, a 2-nitromididazole, and posaconazole, an …

The ability of the Chagas disease agent Trypanosoma cruzi to resist extended in vivo
exposure to highly effective trypanocidal compounds prompted us to explore the potential for …

Many studies have shed light on the mechanisms underlying both immunoprotection and
immune dysregulation arising after Trypanosoma cruzi infection. However, little is known …

Investigations into intracellular replication and differentiation of Trypanosoma cruzi within
the mammalian host have been restricted by limitations in our ability to detect parasitized …

Trypanosoma cruzi parasites utilise de novo pyrimidine biosynthesis to produce DNA and
survive within mammalian host cells. This pathway can be hijacked to assess the replication …